Published in J Psychosoc Oncol on January 01, 2012
Young Adult Female Cancer Survivors' Decision Regret About Fertility Preservation. J Adolesc Young Adult Oncol (2015) 0.80
Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study. Support Care Cancer (2014) 0.75
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol (2010) 3.78
Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer (2014) 2.94
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol (2008) 2.42
New advances in ovarian cancer. Oncology (Williston Park) (2010) 2.27
When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol (2010) 1.98
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 1.95
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 1.81
Robotic versus open radical hysterectomy: a comparative study at a single institution. Gynecol Oncol (2008) 1.68
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer (2010) 1.55
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer (2013) 1.52
Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One (2012) 1.42
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One (2012) 1.31
Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. Gynecol Oncol (2008) 1.25
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res (2008) 1.23
Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol (2006) 1.22
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer (2013) 1.17
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One (2013) 1.11
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2012) 1.10
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol (2009) 1.05
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med (2009) 1.05
Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer (2009) 1.04
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol (2009) 1.03
Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol (2009) 1.01
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol (2010) 1.00
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol (2005) 0.99
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol (2005) 0.99
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol (2005) 0.96
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol (2004) 0.94
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol (2012) 0.94
The Feasibility of Societal Cost Equivalence between Robotic Hysterectomy and Alternate Hysterectomy Methods for Endometrial Cancer. Obstet Gynecol Int (2011) 0.94
Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol (2010) 0.92
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol (2004) 0.91
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol (2008) 0.91
Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr Cancer Ther (2010) 0.91
Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol (2011) 0.90
Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol (2015) 0.90
POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing. Cancer (2014) 0.89
Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes Cancer (2010) 0.89
Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging (2013) 0.88
Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol (2012) 0.88
CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem (2010) 0.87
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig (2011) 0.87
Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Gynecol Oncol (2009) 0.86
Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy. Gynecol Oncol (2006) 0.85
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol (2013) 0.84
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol (2015) 0.84
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol (2005) 0.83
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol (2007) 0.83
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer (2011) 0.83
Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies. Mod Pathol (2010) 0.82
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol (2012) 0.82
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget (2014) 0.82
Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol (2012) 0.81
Venous thromboembolism prophylaxis for laparoscopic surgery: a survey of members of the Society of Gynecologic Oncology. Int J Gynecol Cancer (2013) 0.80
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol (2009) 0.80
A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med (2012) 0.80
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol (2004) 0.80
Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors. Gynecol Oncol (2013) 0.79
The role of para-aortic lymphadenectomy in the surgical staging of women with intermediate and high-risk endometrial adenocarcinomas. Int J Surg Oncol (2013) 0.79
Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs (2013) 0.78
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol (2003) 0.78
Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol (2013) 0.77
Differential hRad17 expression by histologic subtype of ovarian cancer. J Ovarian Res (2011) 0.77
Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med (2009) 0.77
Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep (2011) 0.77
Ovarian cancer clinical practice guidelines. J Natl Compr Canc Netw (2004) 0.77
Health Care Disparities in Hysterectomy for Gynecologic Cancers: Data From the 2012 National Inpatient Sample. Obstet Gynecol (2015) 0.76
Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome. Int J Gynecol Pathol (2017) 0.76
Reply to in-bag morcellation for presumed myoma retrieval at laparoscopy. Cancer (2014) 0.75
Protein kinases and associated pathways in pluripotent state and lineage differentiation. Curr Stem Cell Res Ther (2014) 0.75
Chemotherapy hypersensitivity reactions in ovarian cancer. J Natl Compr Canc Netw (2014) 0.75
Using FastTrack to Implement an Academic Medical Center and Community Health Center Collaborative for Cancer Care Delivery. Healthc (Amst) (2013) 0.75
Unresorbed corpora albicantia mimicking a sonographically solid ovarian mass in a postmenopausal woman. J Ultrasound Med (2004) 0.75
New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.75
Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med (2008) 0.75
Small echogenic foci in the ovaries: correlation with histologic findings. J Ultrasound Med (2004) 0.75